Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs

J.H. Burton, R.O. Venable, D.M. Vail, L.E. Williams, C.A. Clifford, S.M. Axiak-Bechtel, A.C. Avery, and D.H. Thamm

Background: Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic chemotherapy may effectively chemosensitize canine MCT while decreasing cost and adverse effects associated with either agent administered as monotherapy.

Hypothesis/Objectives: The primary study objectives were to (1) identify the maximally tolerated dose (MTD), (2) determine the objective response rate (ORR) and (3) describe the adverse event profile of pulse-administered toceranib phosphate (TOC) combined with lomustine.

Animals: Forty-seven client-owned dogs with measurable MCT.

Methods: Toceranib phosphate was given PO on days 1, 3 and 5 of a 21-day cycle at a target dosage of 2.75 mg/kg. Lomustine was given PO on day 3 of each cycle at a starting dosage of 50 mg/m². All dogs were concurrently treated with diphenhydramine, omeprazole, and prednisone.

Results: The MTD of lomustine was established at 50 mg/m² when combined with pulse-administered TOC; the dose-limiting toxicity was neutropenia. Forty-one dogs treated at the MTD were evaluable for outcome assessment. The ORR was 46% (4 complete response, 15 partial response) and the overall median progression-free survival (PFS) was 53 days (1 to >752 days). On multivariate analysis, variables significantly associated with improved PFS included response to treatment, absence of metastasis, and no previous chemotherapy.

Conclusions and clinical importance: Combined treatment with pulse-administered TOC and lomustine generally is well tolerated and may be a reasonable treatment option for dogs with unresectable or metastatic MCT.

Key words: Cancer; Chemotherapy; Dog; Tyrosine kinase inhibitor.

Abbreviations:
ALT alanine transaminase
ALP alkaline phosphatase
CR complete response
DLT dose-limiting toxicity
ITD internal tandem duplication
MCT mast cell tumor
MTD maximally tolerated dose
ORR objective response rate
OS overall survival
PR partial response
PFS progression-free survival
PD progressive disease
RECIST response evaluation criteria in solid tumors
SD stable disease
TOC toceranib phosphate
TTMR time to maximal response
TKI tyrosine kinase inhibitor

From the Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO (Burton, Venable and Thamm); the School of Veterinary Medicine and the Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI (Vail); the Department of Clinical Sciences, North Carolina State University, Raleigh, NC (Williams); the Red Bank Veterinary Hospital, Tinton Falls, NJ (Clifford); the Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO (Axiak-Bechtel); and the Flint Animal Cancer Center, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO (Avery); Dr. Burton’s present address is Department of Surgical and Radiological Sciences, University of California, Davis, Davis, CA; Dr. Venable’s present address is Arizona Veterinary Oncology, Gilbert, AZ; Dr. Williams’ present address is Veterinary Specialty Hospital of the Carolinas, Cary, NC; Dr. Clifford’s present address is Hope Veterinary Specialists, Malvern, PA.

This was presented in abstract form at the Veterinary Cancer Society meeting, October, 2012, Las Vegas, NV and October, 2013, Minneapolis, MN.

Patients were enrolled at the Flint Animal Cancer Center, Colorado State University Veterinary Medical Center (CSU-VMC), School of Veterinary Medicine, University of Wisconsin-Madison (UW-SVM), Veterinary Medical Teaching Hospital, University of Missouri (MU-VTH), Red Bank Veterinary Hospital and the Veterinary Health Complex, North Carolina State University (NCSU-VHC).

Corresponding author: Dr. D.H. Thamm, Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, 300 W. Drake Road, Fort Collins, CO 80523-1620; e-mail: doug.thamm@colorstate.edu.

Submitted January 30, 2015; Revised April 1, 2015; Accepted May 14, 2015.

Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1111/jvim.13573

Mast cell tumors (MCT) are the most common cutaneous tumors in the dog and are generally successfully treated with wide surgical excision alone.1-3 Therapeutic challenges, however, arise with MCT that are large or infiltrative, high grade, have metastasized beyond the regional lymph node, or are located where wide surgical excision is not possible. Several medical treatments have been studied for MCT in dogs, including corticosteroids alone, lomustine, chlorambucil, hydroxyurea, and vinblastine as well as various combinations of these agents.4-11 Although generally well tolerated, response rates frequently
remain at or below 50% and usually are brief and incomplete. The tyrosine kinase inhibitor (TKI), toceranib phosphate (TOC), has demonstrated single-agent antitumor activity against MCT in dogs, but fewer than half of the dogs with MCT experience objective tumor regression with only 14% experiencing complete responses (CR). The TKI sunitinib and radiation therapy are synergistic in preclinical models of pancreatic adenocarcinoma, soft tissue sarcoma, and breast cancer in humans as well as between TOC and radiation therapy in dogs with MCT. In addition, several studies have identified potentiation of the efficacy of paclitaxel, doxorubicin, and vincristine by the TKI imatinib in human preclinical models of KIT-positive melanoma and Ewing’s sarcoma. Together, these data suggest that combination therapies with TKIs may improve efficacy over single-agent treatments alone.

Clinically relevant adverse effects can be observed with continuous long-term TKI administration, including diarrhea, inappetence, neutropenia, proteinuria, fatigue, and musculoskeletal pain, resulting in the need for drug holidays and dose reductions. Pulse administration of TKIs with chemotherapy potentially may chemo sensitize tumor cells while decreasing cost and toxicity associated with chronic TKI administration.

This phase I/II multicenter clinical trial sought to determine the maximally tolerated dose (MTD), tolerability and adverse event profiles of combined treatment with pulse-administered TOC, and lomustine in dogs with measurable MCT. The second objective of this study was to determine the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in dogs with measurable MCT treated with combined pulse-administered TOC and lomustine, and to identify potential prognostic factors in dogs treated with this combination. We hypothesized that the combination of pulse-administered TOC and lomustine would be well tolerated and efficacious when administered to dogs with cutaneous MCT.

Materials and Methods

Patient Selection

Client-owned dogs with histologically or cytologically confirmed MCT ≥10 mm in longest diameter, where surgical excision was not feasible or was declined by the owner, were considered for enrollment. Eligibility criteria included Veterinary Co-operative Oncology Group – Common Terminology Criteria for Adverse Events (VCOG-CTCAE) constitutional health score of 0 (normal activity) or 1 (mildly decreased from baseline) and life expectancy of >6 weeks. Dogs were required to have adequate hematologic, renal, and hepatic function to safely undergo treatment; defined as ≥2.500 neutrophils/µL, ≥75,000 platelets/µL, PCV ≥28%, serum creatinine concentration ≤2× the upper limit of normal (ULN), total serum bilirubin concentration <1.5x ULN, alanine transaminase (ALT) activity ≤2× ULN, aspartate aminotransferase activity ≤2× ULN, and gamma-glutamyl transferase activity ≤2× ULN.

Baseline evaluations included medical history, physical examination, abdominal ultrasound examination, cytologic evaluation of regional lymph nodes, CBC, serum biochemistry, and urinalysis. Thoracic radiographs were not required as part of the study but were performed by some supervising clinicians as routine staging for MCT. Tumor aspirates also were obtained at the time of enrollment to assess for c-kit gene mutation. The participating institutions’ Animal Care and Use Committees or Clinical Review Boards approved the clinical protocol, and written informed consent was obtained from the owners before patient enrollment.

Phase I Study Design and Treatment Protocol

Dogs were given diphenhydramine 2–4 mg/kg PO q12h, omeprazole 0.7 mg/kg PO q24h, and prednisone 1 mg/kg PO q48h for a minimum of 72 hours before the initiation of the treatment with TOC; these medications were continued throughout the study period. An open-label, phase I, 3+3 dose-escalation design was employed to assess the safety of combination pulse-dosed TOC and lomustine.

Dogs were scheduled to receive TOC 2.75 mg/kg PO once on days 1, 3, and 5 of a 21-day cycle; the TOC dose remained the same throughout the study and was given in 2.75 mg/kg PO. Lomustine dosage was planned in 10 mg/m² increments until the maximally tolerated dose (MTD) of the combination therapy was established. If ≥2 DLTs were noted in the expanded cohort of 6 dogs, dose escalation was continued up to a total of 6 dogs. If no additional DLTs were noted in the expanded cohort of 6 dogs, dose escalation was continued with the same dosage of TOC and an increased dosage of lomustine. If a DLT was observed in 1 dog, the cohort was expanded up to a total of 6 dogs. If no additional DLTs were noted in the expanded cohort of 6 dogs, dose escalation was continued with a higher dosage of lomustine. If ≥2 DLTs were observed in the initial or expanded cohort, case accrual was stopped and the MTD was determined to be the dosage used in previous cohort where <2 DLTs were noted. Escalation of the lomustine dosage was planned in 10 mg/m² increments until the MTD of the combination therapy was established.

Safety Evaluation

Dogs were evaluated 1 week after the first dose of lomustine and a physical examination and CBC were performed. Reevaluation occurred again 3 weeks after the lomustine dose; physical examination, tumor measurements, CBC, and assessment of ALT activity with or without other liver enzymes was performed at that time. Owners completed a quality of life assessment form at each study visit that has been previously described. Adverse events noted on laboratory evaluation, physical examination, or noted by owners were prospectively graded using VCOG-CTCAE v1.0.

For dogs experiencing grade 3 or 4 neutropenia, a 20% dose reduction of lomustine was performed for subsequent dosing cycles. Increases in hepatic transaminase activity were managed at...
the discretion of the attending clinician with lomustine dose reductions, delays in treatment, or both. Either prophylactic or therapeutic treatment with hepatoprotectants was also allowable.

**Antitumor Response Assessment**

Once a MTD was identified, cohort expansion at the MTD was performed according to a Simon’s Minimax design to evaluate the efficacy of pulse-administered TOC and lomustine. Twenty-eight dogs were to be enrolled in the first stage. If ≥11 of the 28 dogs initially enrolled at the MTD experienced a tumor response, the cohort was to be further expanded to include an additional 13 dogs to better define the response to treatment. If <11 of the 28 dogs experienced a response, enrollment would be discontinued.

Tumor response was assessed every 3 weeks in all dogs enrolled in this study using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The longest diameters of the target lesions were documented before treatment initiation with TOC. A CR was defined as the disappearance of all lesions, a partial response (PR) was defined as at least a 30% decrease in the sum of the target lesion diameters, and progressive disease (PD) was defined as ≥20% increase in the sum of the target lesion diameters resulting in the disappearance of all lesions, a partial response (PR) or partial response (PR) and must have persisted disease progression. Dogs experiencing CR were treated with 5 mg/m² pulse-dosed TOC and lomustine once every 3 weeks until disease progression. Dogs experiencing CR were treated with 5 mg/m² pulse-dosed TOC and lomustine for 2 cycles beyond documentation of a clinical CR, whichever was longer, and were evaluated monthly after the last cycle of TOC/lomustine for tumor response assessment. Dogs experiencing PD were removed from the study.

**c-Kit Mutation Status**

**Nucleic Acid Extraction.** Genomic DNA samples were prepared from Wright-Giemsa-stained fine needle aspirates. Slides were confirmed to have ≥10% of the cell population as mast cells. Qiagen AL buffer was applied to the slides, which were then scraped with a straight-edged razor into microcentrifuge tubes. DNA extraction was then performed with a commercial kit according to the manufacturer’s instructions.

**PCR Amplification of c-kit Exons 8 and 11.** Regions of c-kit exons 8 and 11 were amplified with primers directed against sequences flanking the characterized internal tandem duplications (ITDs). The primer pair for exon 8 consisted of (TGACCTATGGGCAATTTCTGTG) coupled with (5'FAM-AATCCGACCGCAAGCCTTATTTCA), resulting in a product of 132 bases. The primer pair for exon 11 consisted of (CACAGAGTGGTGGAGAG) coupled with (VIC-CATGGAAAGCCCCTTTCA), resulting in a product of 92 bases. Amplifications were performed with a commercially available PCR kit. Primer concentrations used were 400 nM each.

Gene scanning analysis was performed using a capillary electrophoresis machine. Amplified fragments were run with Gene Scanmx-600 LIZ size standards. Raw data were analyzed with a commercially available genotype analysis software.

**Statistics**

Continuous data were expressed as median and range, and categorical data as frequencies and percentages. Time to maximal response (TMR) was calculated from the date of treatment initiation to the date the best overall response was first documented. Progression-free survival and OS were calculated from the date of administration of the first dose of TOC to the date of PD or death, respectively. Dogs that were still alive at the time of data analysis were censored at the last date reported to be alive. Dogs that had died were considered to be dead either secondary to their treatment or their disease. Kaplan-Meier estimation was used to estimate and display the distribution of the PFS and OS. Logrank and Cox proportional hazards regression was used to evaluate associations between patient and treatment factors and PFS and OS. Simple regression was first used to determine which covariates to include in the multiple regression model based on an alpha level of 10%. Covariates with P-values < 0.10 in simple regression models were then included in multiple regression models. Multiple regression models were estimated and covariates were removed in a forward and reverse stepwise fashion because of insignificance at the 5% alpha level. Variables with values of P ≤ 0.05 were considered significant. All statistical analyses were performed using commercial software packages.

**Results**

**Patient Population**

A total of 47 dogs were enrolled in the clinical trial from March, 2011 to March, 2013; 13 were enrolled into the dose escalation phase and the remainder into the dose expansion phase. Dogs were enrolled at the Flint Animal Cancer Center at Colorado State University (n = 28), North Carolina State University (n = 8), University of Missouri (n = 5), University of Wisconsin-Madison (n = 4) and Red Bank Veterinary Hospital (n = 2). Patient demographics and tumor characteristics for all dogs enrolled in phase 2 of the clinical trial are described in Table 1.

**Dose Escalation**

The dose escalation cohorts are summarized in Table 2. The MTD of lomustine when combined with pulse-dosed TOC was determined to be 50 mg/m². Eight dogs were enrolled in the first cohort and given lomustine at 50 mg/m². One of the first 3 dogs enrolled experienced a grade 4 neutropenia and 2 dogs subsequently enrolled were unable to be evaluated for safety and efficacy because they were withdrawn from the study before day 7 because of progression of disease. The lomustine dosage was increased to 60 mg/m² in 2 dogs and both dogs in this cohort experienced grade 4 neutropenia. The dosage then was de-escalated to 55 mg/m², at which 2 out of 3 dogs experienced grade 4 neutropenia.

**Cohort Expansion and Outcome**

Having established the MTD, an additional 20 dogs were enrolled into the first phase of the clinical trial cohort expansion and given TOC at the previously described dosing schedule and lomustine at a target dosage of 50 mg/m² once every 3 weeks. Of the first 28 dogs treated with lomustine at 50 mg/m² combined with pulse-administered TOC, 13 dogs had an objective tumor response (10 PR, 3 CR). Because the number of dogs experiencing an objective tumor response was >11, 13 additional dogs were included in the dose expansion phase of the study, resulting in a total of 41 dogs.
evaluable for outcome evaluation at the MTD, because 1 dog was lost to follow-up 1 day after study commencement. The median administered dosage of lomustine was 47.6 mg/m² (range 30.3–54.5 mg/m²) for a median of 3 cycles (range 1–15 mg/m²). The median administered dosage of TOC was 2.65 mg/kg (range 2.5–2.85 mg/kg). Hematologic adverse events were most common with 34 dogs (82.9%) developing some degree of neutropenia 1 week post-lomustine. Eight dogs (19.5%) experienced grade 1 neutropenia, 10 (24.4%) developed grade 2 neutropenia, 7 (17.1%) developed grade 3 neutropenia and 9 (22%) experienced grade 4 neutropenia. Dose reductions were performed for 9 (22%) dogs experiencing neutropenia and no dose delays were performed for management of neutropenia. One dog developed grade 4 anemia which occurred at the time visceral disease progression was noted. Hepatotoxicity also was common, with 24 dogs (59%) developing increases in ALT activity; 9 dogs had severe increases (8 grade 3 and 1 grade 4) in ALT activity. Twelve (50%) dogs had increased ALT activity after 1 dose of lomustine and these increases generally were mild (8 grade 1, 4 grade 2). Seven (29%) dogs developed increased ALT activity after 2 doses, 2 (8%) after 3 doses, and 1 (4%) developed increased ALT activity after 5 doses of lomustine. Increased ALT activity was associated with a lomustine dose decrease (grade 3, n = 1) or dose delay (grade 1, n = 1; grade 2, n = 1; grade 3, n = 5). In addition, 1 dog had grade 4 increased ALT activity and was removed from the study. Hepatoprotectants were not administered prophylactically in this study but were used in the management of hepatotoxicity, with 13 dogs receiving Denamarin® after increases in ALT activity were identified. Adverse events are summarized in Table 3. In summary, dose reductions of lomustine, treatment delays or both were performed for 16 dogs (39%) to manage adverse events in this study; these were implemented at the discretion of the supervising clinician. Seven dogs (17.1%) had a dose reduction of lomustine, 6 dogs (14.6%) had at least 1 treatment cycle delay, and 3 dogs (7.3%) had both a dose reduction of lomustine and a treatment delay performed. No dogs required dose reductions or delays in TOC administration.

Fifteen dogs (36.6%) experienced PR and 4 dogs (9.8%) experienced CR after lomustine and pulse-dose TOC for an ORR of 46%. Of the remaining dogs, 6 had SD, 15 developed PD, and 1 dog was not evaluable for response because of euthanasia by the primary care veterinarian before response assessment. The presence of a c-kit ITD was not associated with response to treatment (P = 0.51). The median TTMR was 21 days (range 7–175 days). The median PFS was 53 days.
The median follow-up time in censored patients was 235 days. On univariate analysis, variables associated with prolonged PFS included response to treatment (Fig 1), absence of metastasis, no previous chemotherapy, and smaller tumor diameter (<6.7 cm; Table 4).

The median PFS was not reached for dogs experiencing CR, was 131.5 days for dogs experiencing PR, and was 77 days for dogs experiencing SD as their best response. Variables associated with increased OS on univariate analysis included no previous chemotherapy and smaller tumor diameter (Table 5). The presence of a c-kit activating mutation was not associated with outcome (P = 0.99 for PFS, P = 0.92 for OS). Variables that remained significant upon multivariate analysis for improved PFS included response, metastasis, and no prior chemotherapy. Response to treatment, small tumor diameter, and no prior treatment were associated with a significantly improved OS (Table 6).

### Table 4. Factors evaluated for effects on progression-free survival.

| Groups   | n  | Median PFS | Logrank P | Logrank HR (95% CI) |
|----------|----|------------|-----------|---------------------|
| Response |    |            |           |                     |
| CR/PR    | 19 | 169        | &lt;0.0001 | 3.496 (2.6–11.88)  |
| SD/PD    | 21 | 42         |           |                     |
| Delay/   |    |            |           |                     |
| Yes      | 16 | 73         |           |                     |
| Reduction|    |            | 0.0653    | 1.899 (0.9875–4.053) |
| Metastasis|   |            |           |                     |
| Yes      | 31 | 47         |           |                     |
| No       | 10 | 104        | 0.0063    | 2.804 (1.396–5.366) |
| Previous |    |            |           |                     |
| Yes      | 12 | 42         |           |                     |
| Chemotherapy | 29 | 77     | 0.0049    | 2.63 (1.586–10.21)  |
| Tumor    |    |            |           |                     |
| ≥6.7 cm  | 21 | 46.5       |           |                     |
| Diameter |    |            |           |                     |
| &lt;6.7 cm| 20 | 77         | 0.0147    | 2.143 (1.219–4.529) |

PFS, Progression-free survival; HR, Hazard ratio; 95% CI, 95% confidence interval; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease.

### Table 5. Factors evaluated for effects on overall survival.

| Groups   | n  | Median ST | Logrank P | Logrank HR (95% CI) |
|----------|----|-----------|-----------|---------------------|
| Response |    |           |           |                     |
| CR/PR    | 19 | 168       |           |                     |
| SD/PD    | 21 | 118       | 0.4962    | 1.36 (0.5795–3.155) |
| Delay/   |    |           |           |                     |
| Yes      | 16 | 222       |           |                     |
| Reduction|    |           | 0.051     | 2.215 (1.002–4.537) |
| Metastasis|   |           |           |                     |
| Yes      | 31 | 114       |           |                     |
| No       | 10 | 361       | 0.0759    | 2.182 (0.9962–4.947) |
| Previous |    |           |           |                     |
| Yes      | 12 | 50        |           |                     |
| Chemotherapy | 29 | 146     | 0.0453    | 2.04 (1.04–5.798)   |
| Tumor    |    |           |           |                     |
| ≥6.7 cm  | 21 | 89        |           |                     |
| Diameter |    |           |           |                     |
| &lt;6.7 cm| 20 | 264       | 0.0195    | 2.162 (1.201–5.034) |

ST, Survival time; HR, Hazard ratio; 95% CI, 95% confidence interval; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease.

### Discussion

Lomustine at 50 mg/m² combined with pulse-administered TOC at 2.75 mg/kg can be safely administered to dogs with MCT with a DLT of neutropenia. A lomustine MTD of 50 mg/m² once every 3 weeks when combined with continuous dosing of TOC at 2.75 mg/kg every other day recently was reported when administered to dogs with tumors other than MCT; the DLT in this phase I study with continuous TOC administration also was neutropenia.²⁹ Other common adverse effects included hepatic and gastrointestinal toxicities, which were not unexpected based on the combination of drugs used in this protocol. Lomustine is known to cause hepatotoxicity in dogs, with reported rates of 83–86%.³⁰⁻³² Twenty-four dogs (59%) developed increases in ALT activity during this study, with 9 dogs having grade 3 or 4 increases. The incidence and severity of increased ALT activity was less than previously reported, which may be due in part to early intervention with hepatoprotectants, dose delays, or both when mild increases in ALT activity developed. The maximally tolerated dosage of lomustine in this protocol was 50 mg/m², which is 28.6–44% lower than lomustine dosages reported elsewhere for treatment of MCT.⁷⁻⁹ This decreased lomustine dosage also may have decreased the frequency and severity of hepatotoxicity observed in this study as compared to previous studies. Dogs in this study also were receiving prednisone concurrently with lomustine and pulse-administered TOC, which routinely causes increases in alkaline phosphatase (ALP) activity and occasionally ALT as well.³³ Some of the increased ALT activity may have been due in part to prednisone administration on ALT activity.

![Fig 1](image-url). Kaplan–Meier curve depicting progression-free survival of dogs whose best response to treatment was either complete response (CR), partial response (PR), or stable disease (SD)/progressive disease (PD). P value indicates logrank test for trend across the 3 groups.
The adverse gastrointestinal effects observed in this study were mild to moderate and primarily occurred after the first dose of lomustine. This observation is in contrast to what has been reported for chronic TOC administration, during which up to 46% of dogs experienced some degree of gastrointestinal toxicity.13 One potential mechanism of gastrointestinal toxicity secondary to TOC is the inhibition of the KIT protein on the interstitial cells of Cajal, resulting in gastrointestinal hypomotility. Pulse administration of TOC may have prevented long-term down-regulation of KIT signaling in the interstitial cells of Cajal, thereby decreasing gastrointestinal toxicity with this dosing schedule.

The ORR of 46% for pulse-administered TOC combined with lomustine is comparable to what previously has been reported for single-agent protocols,5,7,12,13 but considerably higher than that reported with single-agent lomustine in a recent multicenter prospective trial (23%).24 Although a randomized, prospective clinical trial would be required to determine if 1 protocol was superior to the other, combining pulse-administered TOC with lomustine may be appealing to some pet owners who do not want to pursue parenteral chemotherapy for their pet but also cannot financially commit to using TOC as monotherapy caused by the cost of the drug and associated monitoring. Not surprisingly, the presence of metastatic disease and lack of response to therapy were associated with a short PFS in multivariate analysis. Dogs that were previously untreated also had an improved PFS and OS as compared to dogs that had previously received chemotherapy for MCT. These findings suggest that although the combination of pulse-administered TOC and lomustine is efficacious, the combination may not overcome the MCT drug resistance that may have occurred in dogs that have failed other therapies. The presence of a c-kit ITD did not affect PFS or OS for this group of dogs, nor was it associated with response to treatment. This finding is in contrast to a previous publication evaluating TOC monotherapy for MCT in which c-kit mutation was associated with a higher likelihood of response,13 and is in contrast to a study combining TOC and palliative radiation therapy, in which c-kit mutation was associated with an inferior outcome.15 This finding highlights the importance of evaluating prognostic factors such as c-kit mutation status in a context-specific setting, rather than extrapolating from previous studies.

In conclusion, lomustine at a dosage of 50 mg/m² once every 3 weeks combined with pulse-dosed TOC was well tolerated, but the ORR was not superior to single-agent protocols. c-kit gene mutation status did not affect outcome. Notably, pulse administration of TOC was associated with a relatively low incidence of adverse gastrointestinal events, when compared with continuous exposure, and use of a lower dosage of lomustine may have contributed to a lower frequency of severe hepatotoxicity. A prospective, randomized trial evaluating whether this combination is advantageous over either lomustine or TOC alone should be considered based on these results.

### Footnotes

1. Qiagen DNEasy Blood and Tissue kit, Qiagen, Valencia, CA
2. Phusion Blood Direct PCR kit, Thermo Scientific, Waltham, MA
3. ABI Prism 3730xl genetic analyzer, Applied Biosystems, Carlsbad, CA
4. GeneMarker v1.85, SoftGenetics, State College, PA
5. Prism v. 6.0b, GraphPad Software, La Jolla, CA
6. SPSS v. 21, IBM, Armonk, NY
7. Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC

### Acknowledgments

The authors acknowledge Kara Hall, Kim Arnett, Talee Reed, Julie Nettifee-Osborne, Deborah Tate, Dr. Ilene Kurman, Dr. Mairin Miller, and Dr. Kathleen Tsimbas for their assistance in patient recruitment and conduct of this clinical trial. This study was supported by a grant from Zoetis.

Conflict of Interest Declaration: Advisory board membership, consulting, speaker honoraria, travel and accommodations covered or reimbursed apply to D. Vail, D. Thamm and C. Clifford with regard to Zoetis, Inc. (formerly Pfizer Animal Health).

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

### References

1. Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1996;142:1–19.
2. Séguiin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996–1999). J Am Vet Med Assoc 2001;218:1120–1123.
3. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27–40.
4. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994;8:406–408.
5. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor–41 cases (1992–1997). J Vet Intern Med 1999;13:491–497.
6. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumor: 61 cases. J Vet Med Sci 2006;68:581–587.
7. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601–605.
8. Cooper M, Tsai X, Bennett P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumors: 57 cases. Vet Comp Oncol 2009;7:196–206.
9. Rassnick KM, Bailey DB, Russell DS, et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumors. Vet Comp Oncol 2010;8:138–152.
10. Taylor F, Gear R, Hoather T, et al. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumors: 21 cases. J Small Anim Pract 2009;50:284–289.
11. Rassnick KM, Al-Sarrafi R, Bailey DB, et al. Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumors in dogs. Vet Comp Oncol 2010;8:103–111.
12. Smrkovski OA, Essick L, Rohrbach BW, et al. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumors. Vet Comp Oncol 2013; Epub July 12.
13. London CA, Malpus PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856–3865.
14. Cunco KC, Geng L, Fu A, et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 2008;71:873–879.
15. Yoon SS, Stangenberg L, Lee YJ, et al. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009;74:1207–1216.
16. Zwolak P, Jasinski P, Terai K, et al. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer 2008;44:2506–2517.
17. Carlsten KS, London CA, Haney S, et al. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable mast cell tumors. J Vet Intern Med 2012;26:135–141.
18. Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vinceristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751–761.
19. Klosowska-Wardega A, Hasumi Y, Ahgren A, et al. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor. Melanoma Res 2011;21:57–65.
20. Scotlandi K, Manara MC, Strammiello R, et al. C-kit receptor expression in Ewing's sarcoma: Lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003;21:1952–1960.
21. Robat C, London C, Bunting L, et al. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: A phase I dose-finding study. Vet Comp Oncol 2012;10:174–183.
22. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755–2768.
23. Gore ME, Szczyluk C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 2009;10:757–763.
24. Veterinary Cooperative Oncology Group – Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2011; Epub July 20.
25. Vail DM. Cancer clinical trials: Development and implementation. Vet Clin North Am Small Anim Pract 2007;37:1033–1057.
26. Veterinary Cooperative Oncology Group – Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195–213.
27. Lynch S, Savary-Bataille K, Leeuw B, et al. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol 2011;9:172–182.
28. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
29. Pan X, Tsimbas K, Kurzman ID, et al. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose-finding study. Vet Comp Oncol 2014; Epub April 16.
30. Skorupski KA, Hammond GM, Irish AM, et al. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. J Vet Intern Med 2011;25:838–845.
31. Hosoya K, Lord LK, Lara-Garcia A, et al. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine). Vet Comp Oncol 2009;7:244–255.
32. Williams LE, Rassnick KM, Power HT, et al. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006;20:136–143.
33. Solter PF, Hoffmann WE, Chambers MD, et al. Hepatic total 3 alpha-hydroxy bile acids concentration and enzyme activities in prednisone-treated dogs. Am J Vet Res 1994;55:1086–1092.
34. Vail DM, von Euler H, Rusk AW, et al. A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. J Vet Intern Med 2012;26:598–607.